Edgewise Therapeutics, Inc. (EWTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Stockholders held by Edgewise Therapeutics, Inc. on June 4, 2026. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Global Select Market under the symbol EWTX. The filing details the voting results for three proposals submitted to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and shareholder voting outcomes rather than financial performance.
Material Changes and Voting Results
The following matters were voted upon at the Annual Meeting:
- Proposal 1: Election of Class II Directors
- Laura Brege: Elected with 87,300,827 votes For and 3,822,867 Withheld.
- Badreddin Edris, Ph.D.: Elected with 64,082,681 votes For and 27,041,013 Withheld.
- Jonathan Root, M.D.: Elected with 59,213,781 votes For and 31,909,913 Withheld.
- All three directors were elected to serve until the 2029 annual meeting.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the appointment of KPMG LLP for the fiscal year ending December 31, 2026.
- Votes: 99,637,228 For, 1,123 Against, 578,031 Abstain.
- Proposal 3: Advisory Vote on Executive Compensation
- Stockholders approved the compensation of Named Executive Officers on a non-binding basis.
- Votes: 87,055,111 For, 3,491,326 Against, 577,257 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to reporting the results of the shareholder vote.
Key Facts for Investor Verification
- Verify the tenure of the newly elected directors (Laura Brege, Badreddin Edris, and Jonathan Root) through the 2029 annual meeting.
- Confirm the engagement of KPMG LLP as the independent auditor for the fiscal year ending December 31, 2026.
- Note the significant number of "Withheld" votes for Dr. Edris and Dr. Root compared to Ms. Brege, indicating varying levels of shareholder support for specific nominees.
- Review the Company's subsequent filings (e.g., 10-K or 10-Q) for financial data, as this 8-K contains no financial metrics.